# SGT-53 in Children With Recurrent or Progressive CNS Malignancies

> **NCT03554707** · EARLY_PHASE1 · WITHDRAWN · sponsor: **SynerGene Therapeutics, Inc.**

## Conditions studied

- Childhood CNS Tumor

## Interventions

- **GENETIC:** SGT-53
- **RADIATION:** Radiation
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03554707
- **Lead sponsor:** SynerGene Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The grant intended to support this trial as ultimately not funded. This trial was not initiated,. No patients were enrolled.
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03554707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03554707, "SGT-53 in Children With Recurrent or Progressive CNS Malignancies". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT03554707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*